Carcinoma, Non-Small Cell Lung Clinical Trials

76 recruitingLast updated: June 17, 2026

There are 76 actively recruiting carcinoma, non-small cell lung clinical trials across 50 countries. Studies span Phase 2, Phase 1, Phase 3, Not Applicable, Phase 4. Top locations include Houston, Texas, United States, Madrid, Spain, New York, New York, United States. Updated daily from ClinicalTrials.gov.


Carcinoma, Non-Small Cell Lung Trials at a Glance

76 actively recruiting trials for carcinoma, non-small cell lung are listed on ClinicalTrialsFinder across 6 cities in 50 countries. The largest study group is Phase 2 with 28 trials, with the heaviest enrollment activity in Houston, Madrid, and New York. Lead sponsors running carcinoma, non-small cell lung studies include Eli Lilly and Company, Janssen Research & Development, LLC, and Pfizer.

Browse carcinoma, non-small cell lung trials by phase

Treatments under study

About Carcinoma, Non-Small Cell Lung Clinical Trials

Looking for clinical trials for Carcinoma, Non-Small Cell Lung? There are currently 76 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Carcinoma, Non-Small Cell Lung trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Carcinoma, Non-Small Cell Lung clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 76 trials

Recruiting
Phase 1Phase 2

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+1 more
National Cancer Institute (NCI)60 enrolled1 locationNCT06694454
Recruiting
Phase 1Phase 2

KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC450 enrolled46 locationsNCT04165070
Recruiting
Phase 2

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Carcinoma, Non-Small Cell Lung
Bristol-Myers Squibb130 enrolled70 locationsNCT06855771
Recruiting
Phase 1

A Phase I Study of [68Ga]Ga-DWJ155 in Patients With Breast and Lung Cancers

Breast NeoplasmsCarcinoma, Non-Small Cell Lung
Novartis Pharmaceuticals36 enrolled1 locationNCT07117214
Recruiting
Phase 2

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC480 enrolled201 locationsNCT06667076
Recruiting
Phase 2

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 2

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small Cell Lung
Johnson & Johnson Enterprise Innovation Inc.130 enrolled41 locationsNCT06667908
Recruiting

A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC380 enrolled70 locationsNCT07230691
Recruiting
Phase 1Phase 2

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC60 enrolled15 locationsNCT07227025
Recruiting
Phase 1Phase 2

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Non-small Cell Lung CancerCarcinoma, Non-Small Cell LungAdvanced/Metastatic Non-Small Cell Lung Cancer
Pfizer162 enrolled45 locationsNCT07227298
Recruiting

Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy

Carcinoma, Non-Small Cell Lung
Hoffmann-La Roche800 enrolled43 locationsNCT06862869
Recruiting
Phase 3

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Lung CancerNon-small Cell Lung CancerCarcinoma, Non-Small Cell Lung+3 more
Pfizer1,410 enrolled346 locationsNCT07222566
Recruiting
Phase 3

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Eli Lilly and Company700 enrolled361 locationsNCT06890598
Recruiting
Phase 3

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled422 locationsNCT06119581
Recruiting
Phase 3

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Carcinoma, Non-Small Cell Lung
Mirati Therapeutics Inc.630 enrolled353 locationsNCT06875310
Recruiting

Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutations.

Carcinoma, Non-Small Cell Lung
University of Colorado, Denver100 enrolled2 locationsNCT03958565
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 1

Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
The Methodist Hospital Research Institute15 enrolled1 locationNCT06566443
Recruiting
Phase 2

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC96 enrolled32 locationsNCT06780085
Recruiting

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)

Carcinoma, Non-Small Cell Lung
Merck Sharp & Dohme LLC1,065 enrolled47 locationsNCT04165798